title: Vemurafenib-induced pityriasis amiantacea: a case report.
abstract: Vemurafenib, a novel treatment for patients with BRAF-positive metastatic melanoma, is associated with a wide spectrum of cutaneous adverse events both benign and malignant. Vemurafenib-induced pityriasis amiantacea (PA), a scaling reaction of the scalp that may cause temporary or cicatricial alopecia, has not yet been reported in the literature. In the present case, PA was observed two months after the initiation of vemurafenib therapy for metastatic melanoma and managed with symptomatic treatment without the need to cease or modify the vemurafenib dosage.
authors.affiliation: a Department of Dermatology , Faculty of Medicine, Selcuk University , Konya , Turkey.
authors.forename: Özlem
authors.initials: Ö
authors.lastname: Bilgiç
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D010915:Pityriasis / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib
keywords: BRAF inhibitor; cutaneous side effects; dermatitis; eruptive milia; melanoma; photosensitivity; seborrheic dermatitis like eruption; tinea amiantacea